Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flopropione is a phloroglucinol-derived small molecule traditionally used in Japan as an antispasmodic agent for the treatment of biliary and urinary tract disorders. It acts as a catechol-O-methyltransferase (COMT) inhibitor and exhibits musculotropic effects that relax smooth muscle, particularly the sphincter of Oddi. More recently, flopropione has been repositioned for the prevention of cisplatin-induced nephrotoxicity. In this context, it functions as an inhibitor of cysteine conjugate beta-lyase (C-S lyase), an enzyme responsible for metabolizing cisplatin-cysteine conjugates into highly reactive and nephrotoxic thiol compounds. By blocking this bioactivation pathway, flopropione aims to mitigate acute kidney injury in cancer patients receiving cisplatin-based chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flopropione.